Distinct Thresholds Govern Myc's Biological Output In Vivo

Cancer Cell

Volumn 14, Issue 6, 2008, Pages 447-457

  Murphy, Daniel J ^a   Junttila, Melissa R ^a   Pouyet, Laurent ^a   Karnezis, Anthony ^b   Shchors, Ksenya ^a   Bui, Duyen A ^a   Brown Swigart, Lamorna ^a   Johnson, Leisa ^c   Evan, Gerard I ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENENTECH INC   (United States)

Author keywords

CELLBIO; HUMDISEASE; SIGNALING

Indexed keywords

ARF PROTEIN; MYC PROTEIN; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; MOUSE; MOUSE STRAIN; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TISSUE LEVEL;

EID: 56849093474     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2008.10.018     Document Type: Article

References (52)

1. Askew D.S., Ashmun R.A., Simmons B.C., and Cleveland J.L. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6 (1991) 1915-1922
2. Bertwistle D., and Sherr C.J. Regulation of the ARF tumor suppressor in Eμ-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis. Blood 109 (2007) 792-794
3. Bertwistle D., Zindy F., Sherr C.J., and Roussel M.F. Monoclonal antibodies to the mouse p19(Arf) tumor suppressor protein. Hybrid. Hybridomics 23 (2004) 293-300
4. Bissonnette R.P., Echeverri F., Mahboubi A., and Green D.R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359 (1992) 552-554
5. Burns K.A., and Kuan C.Y. Low doses of bromo- and iododeoxyuridine produce near-saturation labeling of adult proliferative populations in the dentate gyrus. Eur. J. Neurosci. 21 (2005) 803-807
6. Chin L., Schreiber-Agus N., Pellicer I., Chen K., Lee H.W., Dudast M., Cordon-Cardo C., and DePinho R.A. Contrasting roles for Myc and Mad proteins in cellular growth and differentiation. Proc. Natl. Acad. Sci. USA 92 (1995) 8488-8492
7. Datta A., Nag A., Pan W., Hay N., Gartel A.L., Colamonici O., Mori Y., and Raychaudhuri P. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J. Biol. Chem. 279 (2004) 36698-36707
8. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., and Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13 (1999) 2658-2669
9. Evan G., and Littlewood T. A matter of life and cell death. Science 281 (1998) 1317-1322
10. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., and Hancock D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69 (1992) 119-128
11. Fanidi A., Harrington E.A., and Evan G.I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359 (1992) 554-556
12. Fasbender A., Lee J.H., Walters R.W., Moninger T.O., Zabner J., and Welsh M.J. Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. J. Clin. Invest. 102 (1998) 184-193
13. Fernandez P.C., Frank S.R., Wang L., Schroeder M., Liu S., Greene J., Cocito A., and Amati B. Genomic targets of the human c-Myc protein. Genes Dev. 17 (2003) 1115-1129
14. ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. Cancer Cell 10 (2006) 113-120
15. Flinn E.M., Busch C.M.C., and Wright A.P.H. myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome. Mol. Cell. Biol. 18 (1998) 5961-5969
16. Harrington E.A., Bennett M.R., Fanidi A., and Evan G.I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 13 (1994) 3286-3295
17. Harrington E.A., Fanidi A., and Evan G.I. Oncogenes and cell death. Curr. Opin. Genet. Dev. 4 (1994) 120-129
18. Hermeking H., and Eick D. Mediation of c-Myc-induced apoptosis by p53. Science 265 (1994) 2091-2093
19. Indra A.K., Warot X., Brocard J., Bornert J.M., Xiao J.H., Chambon P., and Metzger D. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res. 27 (1999) 4324-4327
20. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., Jacks T., and Tuveson D.A. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15 (2001) 3243-3248
21. Jackson E.L., Olive K.P., Tuveson D.A., Bronson R., Crowley D., Brown M., and Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65 (2005) 10280-10288
22. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., and Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410 (2001) 1111-1116
23. Juin P., Hueber A.O., Littlewood T., and Evan G. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev. 13 (1999) 1367-1381
24. Juin P., Hunt A., Littlewood T., Griffiths B., Swigart L.B., Korsmeyer S., and Evan G. c-Myc functionally cooperates with Bax to induce apoptosis. Mol. Cell. Biol. 22 (2002) 6158-6169
25. Kamijo T., Weber J.D., Zambetti G., Zindy F., Roussel M.F., and Sherr C.J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95 (1998) 8292-8297
26. Kamijo T., van de Kamp E., Chong M.J., Zindy F., Diehl J.A., Sherr C.J., and McKinnon P.J. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled ATM function. Cancer Res. 59 (1999) 2464-2469
27. Land H., Parada L.F., and Weinberg R.A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304 (1983) 596-602
28. Lawlor E.R., Soucek L., Brown-Swigart L., Shchors K., Bialucha C.U., and Evan G.I. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. Cancer Res. 66 (2006) 4591-4601
29. Lewandoski M., Wassarman K.M., and Martin G.R. Zp3-cre, a transgenic mouse line for the activation or inactivation of loxP-flanked target genes specifically in the female germ line. Curr. Biol. 7 (1997) 148-151
30. Littlewood T.D., Hancock D.C., Danielian P.S., Parker M.G., and Evan G.I. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23 (1995) 1686-1690
31. Liu J., and Levens D. Making myc. Curr. Top. Microbiol. Immunol. 302 (2006) 1-32
32. Lowe S.W., and Sherr C.J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13 (2003) 77-83
33. Lowe S.W., Cepero E., and Evan G. Intrinsic tumour suppression. Nature 432 (2004) 307-315
34. Moore J.P., Hancock D.C., Littlewood T.D., and Evan G.I. A sensitive and quantitative enzyme-linked immunosorbence assay for the c-myc and N-myc oncoproteins. Oncogene Res. 2 (1987) 65-80
35. Nesbit C.E., Tersak J.M., and Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene 18 (1999) 3004-3016
36. Pelengaris S., Khan M., and Evan G.I. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109 (2002) 321-334
37. Penn L.J., Brooks M.W., Laufer E.M., and Land H. Negative autoregulation of c-myc transcription. EMBO J. 9 (1990) 1113-1121
38. Popescu N.C., and Zimonjic D.B. Chromosome-mediated alterations of the MYC gene in human cancer. J. Cell. Mol. Med. 6 (2002) 151-159
39. Qi Y., Gregory M.A., Li Z., Brousal J.P., West K., and Hann S.R. p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431 (2004) 712-717
40. Queva C., Hurlin P.J., Foley K.P., and Eisenman R.N. Sequential expression of the MAD family of transcriptional repressors during differentiation and development. Oncogene 16 (1998) 967-977
41. Rabbitts P.H., Watson J.V., Lamond A., Forster A., Stinson M.A., Evan G., Fischer W., Atherton E., Sheppard R., and Rabbitts T.H. Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. EMBO J. 4 (1985) 2009-2015
42. Ramsay G., Evan G.I., and Bishop J.M. The protein encoded by the human proto-oncogene c-myc. Proc. Natl. Acad. Sci. USA 81 (1984) 7742-7746
43. Sarkisian C.J., Keister B.A., Stairs D.B., Boxer R.B., Moody S.E., and Chodosh L.A. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat. Cell Biol. 9 (2007) 493-505
44. Schmitt C.A., McCurrach M.E., de Stanchina E., Wallace-Brodeur R.R., and Lowe S.W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13 (1999) 2670-2677
45. Spencer C.A., and Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res. 56 (1991) 1-48
46. Srinivas S., Watanabe T., Lin C.S., William C.M., Tanabe Y., Jessell T.M., and Costantini F. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 1 (2001) 4
47. Tran P.T., Fan B.C., Bendapudi P.K., Koh S., Komatsubara K., Chen J., Horng G., Bellovin D.I., Giuriato S., Wang C.S., et al. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS ONE 3 (2008) e2125
48. Vastrik I., Kaipainen A., Penttila T.L., Lymboussakis A., Alitalo R., Parvinen M., and Alitalo K. Expression of the mad gene during cell differentiation in vivo and its inhibition of cell growth in vitro. J. Cell Biol. 128 (1995) 1197-1208
49. Wagner A.J., Small M.B., and Hay N. Myc-mediated apoptosis is blocked by ectopic expression of bcl-2. Mol. Cell. Biol. 13 (1993) 2432-2440
50. Wagner A.J., Kokontis J.M., and Hay N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev. 8 (1994) 2817-2830
51. Weber J.D., Taylor L.J., Roussel M.F., Sherr C.J., and Bar-Sagi D. Nucleolar ARF sequesters Mdm2 and activates p53. Nat. Cell Biol. 1 (1999) 20-26
52. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., and Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12 (1998) 2424-2433